

Decision to increase our capital through third-party allocation Building awareness and strengthening the test supply system

At an Extraordinary General Meeting of Shareholders held today, HIROTSU BIO SCIENCE INC. (headquartered in Chiyoda-ku, Tokyo; President: Takaaki Hirotsu), supplier of the N-NOSE® primary cancer screening test that utilizes the scent detection abilities of nematodes, made the decision to increase its capital through the allocation of new shares to several third-party investors and business corporations.

N-NOSE, a simple at-home screening test, has seen a steady increase in the number of test takers since its introduction in 2020. To deliver this new method, which enables the early detection and treatment of cancer, to even more people, we will work to build awareness of N-NOSE through vigorous promotional campaigns—while at the same time strengthening our test supply system.

We will forge ahead to promote the uptake of N-NOSE, with the goal of realizing a future where many people can access tests without excessive fear of cancer, and can get back to their lives as quickly as possible in the event that cancer is diagnosed.

■ About N-NOSE nematode cancer screening

N-NOSE is the world's first primary cancer screening test that utilizes "nematodes," microorganisms that are highly sensitive to the odor of cancer in human urine. Clinical research has shown that nematodes even respond to early-stage cancer (stages 0 and I), which is difficult to detect with conventional screening methods.

The fact that cancer risk can be assessed in one test, regardless of the location in the body,* is another strength that sets N-NOSE apart from other tests.

* Types of cancer that nematodes are known to respond to: stomach, colorectal, lung, breast, pancreatic, liver, prostate, uterine, esophageal, gall bladder, bile duct, kidney, bladder, ovarian, oral/pharyngeal—15 types of cancer (as of September 2019)

■ HIROTSU BIO SCIENCE INC. Official Company Website <https://hbio.jp/>

■ See here for information about the N-NOSE cancer screening test <https://www.n-nose.com/lp/>

* N-NOSE is a registered trademark of HIROTSU BIO SCIENCE INC. Ltd.

Company Name	HIROTSU BIO SCIENCE INC.
Address	22F The New Otani GARDEN COURT, 4-1 Kioicho Chiyoda-ku, Tokyo, 102-0094, Japan
President & CEO	Takaaki Hirotsu
Incorporated	August 2016
Business Overview	Biological Diagnostics Research: Research, development, and sale of cancer diagnostic test utilizing <i>C. elegans</i> and <i>C. elegans</i> olfactory sensors
URL	https://hbio.jp